| 3.82 -0.08 (-2.05%) | 08-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.06 | 1-year : | 5.92 |
| Resists | First : | 4.34 | Second : | 5.06 |
| Pivot price | 3.96  |
|||
| Supports | First : | 3.61 | Second : | 3.17 |
| MAs | MA(5) : | 3.99 |
MA(20) : | 3.89 |
| MA(100) : | 3.78 |
MA(250) : | 2.91 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 44.7 |
D(3) : | 55.9 |
| RSI | RSI(14): 48.3 |
|||
| 52-week | High : | 4.84 | Low : | 1.29 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ADAG ] has closed above bottom band by 28.4%. Bollinger Bands are 24.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.98 - 4 | 4 - 4.03 |
| Low: | 3.75 - 3.79 | 3.79 - 3.81 |
| Close: | 3.77 - 3.82 | 3.82 - 3.86 |
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Thu, 20 Aug 2026
Adagene (NASDAQ: ADAG) officer to sell 131K ADS to cover option taxes - Stock Titan
Thu, 20 Aug 2026
Adagene to Participate in Three Upcoming Investor Conferences - The Manila Times
Wed, 19 Aug 2026
Adagene (NASDAQ: ADAG) officer plans August ADS sell-to-cover - Stock Titan
Sat, 15 Aug 2026
Adagene (ADAG) Holds Near Support: A Modest Pullback in a Biotech Consolidation - Straddle Setup - vinanet.vn
Fri, 14 Aug 2026
Adagene Stock Price Forecast. Should You Buy ADAG? - StockInvest.us
Thu, 06 Aug 2026
Adagene (NASDAQ:ADAG) CEO Peter Luo Acquires 22,966 Shares - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 66 (M) |
| Held by Insiders | 4.217e+007 (%) |
| Held by Institutions | 21.2 (%) |
| Shares Short | 2,080 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.195e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -220.8 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 23.9 % |
| Return on Equity (ttm) | -14 % |
| Qtrly Rev. Growth | 9.29e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -50 |
| EBITDA (p.s.) | 1.62982e+007 |
| Qtrly Earnings Growth | -0.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.08 |
| Price to Cash Flow | 1.63 |
| Dividend | 0 |
| Forward Dividend | 2.29e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|